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SV‑HotSpot: detection
and visualization of hotspots
targeted by structural variants
associated with gene expression
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Scott M. Dehm 7,8, Jingqin Luo 9,10, Felix Y. Feng4,11, Ha X. Dang 1,2,10,13 &
Christopher A. Maher 1,2,10,12,13*

6

,

Whole genome sequencing (WGS) has enabled the discovery of genomic structural variants (SVs),
including those targeting intergenic and intronic non-coding regions that eluded previous exome
focused strategies. However, the field currently lacks an automated tool that analyzes SV candidates
to identify recurrent SVs and their targeted sites (hotspot regions), visualizes these genomic
events within the context of various functional elements, and evaluates their potential effect on
gene expression. To address this, we developed SV-HotSpot, an automated tool that integrates
SV candidates, copy number alterations, gene expression, and genome annotations (e.g. gene and
regulatory elements) to discover, annotate, and visualize recurrent SVs and their targeted hotspot
regions that may affect gene expression. We applied SV-HotSpot to WGS and matched transcriptome
data from metastatic castration resistant prostate cancer patients and rediscovered recurrent SVs
targeting coding and non-coding functional elements known to promote prostate cancer progression
and metastasis. SV-HotSpot provides a valuable resource to integrate SVs, gene expression, and
genome annotations for discovering biologically relevant SVs altering coding and non-coding genome.
SV-HotSpot is available at https://github.com/ChrisMaherLab/SV-HotSpot.
Structural variations (SVs) are genomic rearrangements that involve large chunks of DNA. These include deletion
(loss of a genomic segment), duplication (gain multiple copies of a genomic segment), insertion (addition of a
DNA sequence to the genome), inversion (one end of a genomic segment is reversed with the other end), and
translocation (genomic rearrangement involving one or more chromosomes)1. SVs are known to contribute to
phenotypic differences and various diseases including cancers2,3.
WGS has enabled comprehensive identification of various types of SVs targeting both the coding and noncoding tumor genome that may affect the activity or function of key driver oncogenes and tumor suppressors.
This was demonstrated in a recent study of advanced prostate cancer integrating WGS, whole transcriptome,
and ChIP-Seq data that showed tandem duplications involving non-coding regulatory regions are significantly
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Figure 1.  Overview of the SV-HotSpot pipeline. Recurrent (hotspot) SVs are first identified via a peak calling
approach (detection), then subsequently annotated with genes and regulatory elements such as enhancers
(annotation), evaluated for association with nearby gene expression (association evaluation) and visualized
(visualization).
associated with the expression of the androgen receptor (AR), a key driver of prostate cancer progression and
metastasis4,5. However, reproducibly performing such integrative analyses on the increasing quantity of whole
genome data sets is limited by the current lack of automated tools for the discovery, visualization, and interpretation of recurrent SVs and their frequent targeted sites (hotspot regions).
To address this limitation, we developed SV-HotSpot, an automated tool that integrates multiple data types
including SV candidates, gene expression, copy number alterations, and genome annotations to identify, annotate, and visualize recurrent SVs and their targeted hotspot regions and assess their potential consequences on
the expression of nearby genes. We applied SV-HotSpot to the whole genome and transcriptome sequencing
data from 101 metastatic prostate cancer patients4 and rediscovered both coding and non-coding recurrent SVs
known to drive prostate cancer progression.

Results

Hotspots of structural variations in metastatic prostate cancer. SV-HotSpot enumerates SVs targeting genomic regions and utilizes a peak calling algorithm to identify regions with elevated frequency of these
events (hereby referred to as peaks or hotspots, see Methods, Fig. 1). To demonstrate that SV-HotSpot is able to
detect biologically relevant recurrent SVs, we applied it to WGS and matched RNA-Seq data from 101 metastatic
prostate cancer patients4. To identify peaks corresponding to regulatory regions, we additionally included annotated enhancers6 and H3K27ac ChIP-Seq (Chromatin Immunoprecipitation Sequencing) data from prostate
cancer patients7.
In total, we identified 296 SV hotspot sites associated with altered expression of 379 nearby genes (Fig. 2,
Supplementary Tables S1, S2). SV-HotSpot identified and highly ranked hotspot sites harboring SVs associated
with expression of many genes known to drive prostate cancer progression, metastasis, and treatment resistance
(Fig. 2, Supplementary Table S1). Interestingly, various SV types were found to be recurrent and associated with
altered expression of tumor suppressors and oncogenes including tandem duplication, chromosomal translocation, and copy number alteration.
Hotspots of tandem duplications targeting genes and regulatory elements. Recent studies highlighted the critical roles of tandem duplications in cancers including prostate cancer4,5,8,9. SV-HotSpot
identified various hotspots of tandem duplications targeting both coding and non-coding regions in metastatic
prostate cancer. Most notably, SV-HotSpot detected a peak of recurrent SVs primarily comprised of tandem
duplications targeting a non-coding enhancer located at ~ 625 kb upstream of AR, a key driver of prostate cancer
progression, treatment resistance, and m
 etastasis10 (Fig. 3). This region was also found to be amplified in 81%
of patients (Fig. 3a, top track). SV-HotSpot detected a strong association between the presence of tandem duplications or copy number gain in this region with increased AR expression (Fig. 3b–d). Moreover, SV-HotSpot
annotated this region with an active enhancer and an enriched H3K27ac occupancy (Fig. 3a, bottom two tracks).
These results are consistent with the recent discovery of an AR enhancer that regulates AR gene expression and
is highly frequently duplicated in prostate cancer metastasis4,5,11.
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Figure 2.  SV-HotSpot identifies hotspots of recurrent SVs associated with genes well characterized in
metastatic prostate cancer. The circos plot (top panel) shows the percentage of samples harboring any type of
SVs (outer track) or individual types of SVs (inner tracks) targeting genomic windows. Genes known in prostate
cancer and found to have altered expression in the presence of SVs targeting hotspots are annotated in the outer
gene track (red—up-regulated in presence of SVs, blue—down-reguated in presence of SVs, *—3′ truncated in
fusion leading to lower gene expression estimate). The bottom panel shows numbers of SV hotspots and genes
associated with these hotspots for individual chromosomes.

In addition to the rediscovery of the AR enhancer, SV-HotSpot also detected peaks of frequent tandem
duplications targeting both the coding and non-coding regions of MYC and FOXA1 loci (Fig. 4, Supplementary Tables S1, S2). Interestingly, SV-HotSpot reported an association of tandem duplication targeting both
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Figure 3.  SV-HotSpot detects and visualizes recurrent SVs targeting the non-coding AR enhancer and is
associating with increased AR expression. (a) Visualization of recurrent SVs targeting the peak (bounded by
vertical dashed lines). From top to bottom are aggregation of copy number alterations, pileup of duplication/
deletion regions, aggregation of duplication/deletion regions, aggregation of all types of SVs, H3K27ac histone
modification ChiP-Seq coverage, and enhancer annotation from Genehancer database. DUP—duplication,
DEL—deletion, INS—insertion, INV—inversion, and BND—translocation (b) Comparison of AR expression
between samples with SVs targeting the peak and those lacking SVs targeting AR enhancer peak. (c)
Comparison of AR expression between samples with different types of SVs targeting the peak. (d) Comparison
of AR expression between samples grouped by the presence/absence of copy number targeting AR gene body
and the peak. The whole figure is the direct output of SV-Hotspot visualization.
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Figure 4.  SV-HotSpot detects recurrent SVs targeting FOXA1 locus. (a) Visualization of FOXA1 locus. From
top to bottom are pileup of duplication/deletion, aggregation of sample counts for different SV types, H3K27ac
ChiP-Seq coverage from primary prostate cancer patients, enhancer annotation from GeneHancers. (b)
Comparison of FOXA1 expression between samples harboring SVs and those do not (restricted to samples in
which FOXA1 is copy neutral).

coding and non-coding regions of FOXA1 locus with increased gene expression (Fig. 4), consistent with a recent
report12. MYC was found to be overexpressed in the presence of copy number gain in its hotspot locus. There
was also an enrichment of tandem duplication targeting both coding and non-coding regions near MYC (Supplementary Table S2).

Hotspots of deletions and translocations associated with ETS gene fusions. ETS gene fusions
are well characterized somatic genome rearrangements that drive prostate cancer tumorigenesis and defines
a distinct molecular subtype13–15. SV-HotSpot identified and highly ranked hotspots that harbor deletions or
chromosomal translocations resulting in gene fusions and increased expression of ETS transcription factor family genes. For instance, SV-HotSpot reported the highest ranked peak in chromosome 21 consisting primarily
of recurrent deletion events that targeted the genomic region between TMPRSS2 and ERG genes corresponding to the TMPRSS2-ERG fusion (Fig. 5a). Deletion of the region between TMPRSS2 and ERG was found to be
strongly associated with increased ERG expression (Fig. 5a). There was also an enrichment of translocations at
ERG locus that were found to be associated with increased ERG expression. These translocations included events
corresponding to ERG gene fusions with different 5′ partner genes (Fig. 5a).
Additionally, SV-HotSpot identified hotspots targeting other ETS genes including ETV1 and ETV4
(Fig. 5b,c, Supplementary Table S1). Interestingly, while many types of SVs were observed in ETV1 and ETV4
loci, only chromosomal translocations were found to be associated with increased expression of these genes.
These enriched translocations corresponded to the inter-chromosomal rearrangements that created ETV1 gene
fusions (10 patients, 10%, Fig. 5b) and ETV4 gene fusions (6 cases, 6%, Fig. 5c).
Hotspot of structural variations disrupting tumor suppressors. Tumor suppressor genes are often
inactivated in cancers by various mechanisms including structural r earrangements4,16,17. SV-HotSpot detected
hotspot sites associated with decreased expression of well-characterized tumor suppressor genes including
PTEN, TP53, RB1, and CDKN1B (Fig. 6, Supplementary Table S1). It is notable that various SV types were found
to target PTEN and TP53 loci and regardless of the SV types, events targeting these tumor suppressors often
found to be associated with decreased gene expression (Fig. 6). For example, all types of SVs targeting PTEN
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Figure 5.  SV-HotSpot detects recurrent deletions and translocations corresponding to the ETS family gene
fusions. From left to right are results for ERG (a), ETV1 (b) and ETV4 (c). In each panel, from top to bottom are
(1) stack histogram of sample counts for different types of SVs within the peak (bounded by black dashed lines),
(2) comparison of expression of the gene between samples harboring individual SV types and those without
any SVs (restricted to samples whose gene is copy neutral), and (3) list of gene fusions in cohort whose 3′
partner is the gene (not part of SV-HotSpot visualization). ERG hotspot is enriched for deletions corresponding
to TMPRSS2-ERG fusions and translocations including those that create—ERG fusions with different 5′
partners, all associated with increased ERG expression. ETV1 and ETV4 peaks were enriched for translocations
corresponding to various fusions and associated with increased gene expression. Note that we used expression
of ERG, ETV1, and ETV4 from the original publication that was normalized using the full length genes, and
thus could be lower than the true fusion expression. This does not change our conclusion as the actual effect of
translocations on fusion expression could be higher.
hotspot were associated with decreased PTEN expression including deletion, duplication, translocation, and
inversion (Fig. 6a, Supplementary Table S1). This is consistent with previous report that PTEN is often disrupted
by various forms of chromosomal r earrangements4,16. Similarly, TP53 expression was decreased in the presence
of deletion, translocation, and inversion (Fig. 6b, Supplementary Table S1).
Taken together, via reanalysis of public datasets, we showed that SV-HotSpot was able to detect hotspots
of recurrent SVs known to contribute to prostate cancer development, progression, metastasis, and treatment
resistance.
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Discussion

Here, we present SV-HotSpot, an automated pipeline to identify, annotate, and visualize hotspots of recurrent SVs
and evaluate their potential consequences on the expression of nearby genes. Despite the great success of recent
studies in identifying recurrent SVs and assessing their i mpact4,18, these approaches require significant amount
of work and ad-hoc analyses to integrate multiple types of data and evaluate the potential effect of SVs on gene
expression. SV-HotSpot seamlessly integrates and analyzes multiple data types including SV candidates, gene
expression, copy number alterations, and functional elements to discover recurrent SV hotspots. Additionally,
it comprehensively evaluates the associations between recurrent SVs and various genome annotation/functional
elements and potential consequence on gene expression. Furthermore, SV-HotSpot provides useful visualizations to facilitate the interpretation of the results. As a fully automated tool, SV-HotSpot allows for customized
and reproducible analyses.
SV-HotSpot uses a sliding window approach that is a generalization of the frequently used genomic binning
approach and allows smoothing of the sample counts for effective peak calling. The use of peak calling algorithm
to identify recurrent SVs in SV-HotSpot enables systematic identification of regions with statistically elevated
frequency of SVs that are more likely functional. This approach is similar to those employed by GISTIC tool
to identify genes recurrently targeted by copy number alteration19. Compared with GISTIC which focuses on
identification of focal copy number alteration, SV-HotSpot additionally integrates a broad spectrum of structural
variations, gene expression, and regulatory elements, and thus was able identify other types of recurrent SVs targeting regulatory elements driving gene expression such as tandem duplication of the AR enhancer. Our approach
is also complementary to existing network biology approaches such as those utilizing molecular interaction data
and information flow method to find association between genes and diseases20.
Through our reanalysis of metastatic prostate cancer patient data, we demonstrated the utility of SV-HotSpot
for detecting biologically relevant and well-characterized recurrent SVs that regulate the expression of nearby
genes. We identified key prostate cancer driver genes as the most significantly associated genes with their commonly known recurrent SVs including tandem duplication of the AR enhancer, deletion of the TMPRSS2-ERG
region, and genomic disruption of PTEN. Moreover, our thorough evaluation of expression association allowed
us to identify specific types of SVs known to affect gene expression including those with lower frequency such
as translocations resulting in gene fusions of ETV1 and ETV4, and tandem duplication affecting FOXA1. Overall, SV-HotSpot is a valuable tool for the cancer research community to integrate the growing whole genome,
transcriptome, and epigenetic data to discover biologically relevant SV hotspots. Although the tool was applied
to human cancer data in this study, it can also be applied to data from other species and diseases.

Methods

SV-HotSpot consists of four main steps (Fig. 1): (1) detection of SV hotspots, (2) annotation of SV hotspots, (3)
evaluation of the association of hotspot SVs on expression of nearby genes, and (4) visualization.
In the first step, SV-HotSpot identifies regions with elevated frequency of SVs by utilizing a peak calling
approach on counts of samples harboring SVs targeting sliding windows over each chromosome. First, it uses the
SV candidates (in BEDPE, Browser Extensible Data Paired-End format) as an input and counts the number of
samples harboring SV breakpoints (in the case of translocations, insertions, and inversions) or regions (in the case
of duplications and deletions) overlapping with sliding windows. The entire duplication/deletion regions were
considered because these events directly affect the contained genome elements by changing their copy numbers
while other events only potentially affect elements near their break ends. SV-HotSpot then applies the peakPick
peak calling algorithm21 to identify windows (referred to as ‘peaks’ thereafter) where counts are significantly
higher than those of the surrounding windows. Peaks occurring in at least a certain percentage of SV samples
(defined by users) are identified as potential peaks. Once all potential peaks are identified, SV-HotSpot applies a
peak merging algorithm to group adjacent peaks with similar sample counts, as those are likely resulted from the
same genome rearrangements that target the same sites. The peak merging algorithm works by first identifying
clusters of adjacent peaks where any two contiguous peaks are within a predefined distance. Next, it selects the
top peak (peak with the highest sample count) among a peak cluster and moves upstream and downstream to
merge peaks until it observes k peaks (k is small, e.g. 1–3, predefined) with significant change of sample counts
compared with the top peak (predefined parameter delta, e.g. 5%). This process is repeated until no peaks in the
cluster remain. The merged peaks are then considered final peaks for subsequent analyses.
In the second step, identified peaks are annotated with nearby genes and overlapping regulatory elements
such as enhancers and promoters, provided as input in BED (Browser Extensible Data) format using BEDTools22.
All annotated peaks are then summarized and output in BED format.
In the third step, gene expression and copy number data are incorporated to evaluate if the presence of SVs at
each peak is associated with altered expression of each nearby gene. A Wilcoxon rank-sum test or t-test (chosen
by users) is used to compare the expression of the nearby gene between samples harboring and not harboring
a hotspot SV. The same test is also performed within sample stratifications based on copy number status (gain,
loss, or neutral) of the nearby gene. More specifically, SV-HotSpot applies 12 different comparisons (illustrated
below) in order to determine the association between a hotspot and a nearby gene.
1. Comparison of the expression of a nearby gene between samples harboring hotspot SVs and those not harboring hotspot SVs without considering copy number status of the gene to determine the overall association
between recurrent SVs and the expression of the gene.
2. Similar to (1), five comparisons are also performed between samples harboring each of the five individual SV
types (duplication, deletion, translocation, insertion, and inversion) targeting the hotspot and those without
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any SVs targeting the hotspot to identify whether the overall expression association is derived by specific SV
types.
3. Comparison of the expression of a nearby gene between samples harboring hotspot SVs and those not
harboring hotspot SVs but only among samples without copy number alteration of the gene to determine
whether the association is derived by SVs without the confounding impact of copy number alterations of
the gene.
4. Similar to (3), five comparisons are also performed between samples harboring each of the five individual SV
types (duplication, deletion, translocation, insertion, and inversion) targeting the hotspot and those without
any SVs targeting the hotspot to identify whether the expression association is derived by specific SV types.
We determine that the presence of SVs at a peak is associated with the expression of a nearby gene if any of
the above comparisons results in the rejection of the null hypothesis that there is no difference in gene expression between groups. To achieve this, the Fisher’s method23 is used to combine the p-values of these tests.
Subsequently, the false discovery rate (FDR) was estimated using the Benjamini–Hochberg24 using the Fisher’s
combined p-values.
Additionally, SV-HotSpot groups dependent peaks that are likely driven by the same SV events and have
similar consequences on the expression of nearby genes into peak families. To achieve this, after the peaks are
identified, those associated with the same gene are tested for dependency using a Fisher’s exact test. If peaks are
found to be dependent (significant overlap of the samples harboring SVs between the peaks), they are grouped
as a peak family. The top-ranked peak (the peak with highest count of samples harboring the hotspot SVs) is
reported as the representative of the peak family.
Finally, SV-HotSpot generates multiple visualizations (Fig. 2 top panel, Fig. 3) for interpretation of the
genomic context and the association between SVs and gene expression. In these visualizations, SV-HotSpot
overlays multiple tracks to show copy number alterations, SV breakpoint aggregation, segments of duplications
and deletions, gene and regulatory element annotation, and ChIP-Seq coverage in close proximity to the peaks
and its nearby genes (Fig. 3a). In addition, the expression of nearby genes is plotted to highlight associations
with recurrent SVs (Fig. 3b), with different types of SVs (Fig. 3c), and with copy number status of both the peak
and nearby genes (Fig. 3d). SV-HotSpot also provides an additional visualization of the distribution of identified
peaks on each chromosome (Fig. 2, top panel). Furthermore, SV-HotSpot generates a custom track file for each
chromosome that can be viewed on the UCSC Genome Browser.
For analyses reported in the Results section, SV-HotSpot was run using a sliding window size of 100 kb, step
size of 30 kb, peak merging distance of 50 kb, default parameters for peakPick, and peak merging parameters
k = 1, delta = 5%. Only peaks smaller than 500 kb (except for those associated with altered expression of a COSMIC census gene25) and present in at least 15% of samples with an FDR < 0.05 and at least one of 12 expression
associations significant at a p-value < 0.05 (Wilcoxon test) were retained. Additionally, only genes with mean
expression > 10 TPM (Transcripts Per Million) in a group from a significant comparison were retained.

Data availability

SV-HotSpot is a Linux-based command-line pipeline implemented in R and Perl and can be run as a Docker
container or Bioconda package. SV-HotSpot is available at https://github.com/ChrisMaherLab/SV-HotSpot.
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